Twelve patients operated for gastrointestinal carcinoid tumors are analyzed retrospectively. Clinically four of the cases (33%) were with signs of bowel obstruction, 4 (33%)--with signs of acute appendicitis, 3 (25%)--with signs of gastric outlet obstruction, and one (9%) with a picture of perforative peritonitis. Carcinoid syndrome was observed in two cases (17%). Five of the tumors (42%) were localized in the small intestine, 4 (33%)--in the appendix and 3 (25%)--in the duodenum. Small bowel resection was performed in 5 cases (42%), appendectomy--in 4 (33%), hemiresection of the duodenum--in 2 (17%) and duodenotomy with excision of the tumor and pyloroplasty--in one. In 2 cases liver metastases were found, and in one--multiple (3) tumors in the gut.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The exceptionally rare phenomenon of well-differentiated colon neuroendocrine tumors.
J Neuroendocrinol
January 2025
Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Colonic neuroendocrine tumors (NETs), excluding rectal NETs, are often described as relatively common and aggressive, with inferior median survival compared with other gastrointestinal (GI) primary sites. However, epidemiological databases may conflate well-differentiated NETs with poorly differentiated neuroendocrine carcinomas (NECs), leading to a lack of precise data on the prevalence, clinical behavior, and prognosis of well-differentiated colonic NETs. We analyzed a large institutional database to identify patients with well-differentiated NETs originating in the colon, excluding rectal NETs.
View Article and Find Full Text PDFEverything you ever wanted to know about cancer stem cells in neuroendocrine neoplasms but were afraid to ask.
Endocr Oncol
January 2024
Centro de Investigación Biomédica en Red, CIBERONC, ISCIII, Madrid, Spain.
While the role of cancer stem cells (CSCs) in tumorigenesis, chemoresistance, metastasis, and relapse has been extensively studied in solid tumors, such as adenocarcinomas or sarcomas, the same cannot be said for neuroendocrine neoplasms (NENs). While lagging, CSCs have been described in numerous NENs, including gastrointestinal and pancreatic NENs (PanNENs), and they have been found to play critical roles in tumor initiation, progression, and treatment resistance. However, it seems that there is still skepticism regarding the role of CSCs in NENs, even in light of studies that support the CSC model in these tumors and the therapeutic benefits of targeting them.
View Article and Find Full Text PDFSmall intestine neuroendocrine tumours (SI-NETs) are often diagnosed late with a UK median of 3 years and high misdiagnosis rates. Previous studies, largely based on patient surveys, offer little data on improving diagnosis. In 2017, the South Wales NET service underwent a nationally commissioned, systematic transformation, aiming to improve diagnosis through the development of a gastroenterology and surgical referral network, and education of these specialities.
View Article and Find Full Text PDFAGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review.
Gastroenterology
February 2025
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California.
Description: Gastric cancer (GC) is a leading cause of preventable cancer and mortality in certain US populations. The most impactful way to reduce GC mortality is via primary prevention, namely Helicobacter pylori eradication, and secondary prevention, namely endoscopic screening and surveillance of precancerous conditions, such as gastric intestinal metaplasia (GIM). An emerging body of evidence supports the possible impact of these strategies on GC incidence and mortality in identifiable high-risk populations in the United States.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!